Francisco David 4
4 · Organogenesis Holdings Inc. · Filed Feb 21, 2025
Insider Transaction Report
Form 4
Francisco David
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-02-19+170,841→ 170,841 totalExercise: $3.53Exp: 2035-02-19→ Class A Common Stock (170,841 underlying) - Award
Class A Common Stock
2025-02-19+165,156→ 559,095 total
Footnotes (2)
- [F1]Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2025.
- [F2]The option becomes exercisable in equal annual installments over four years beginning February 15, 2025.